
EX-99.1 Page 47 of 104




EX-99.1 Page 48 of 104




EX-99.1 Page 49 of 104




EX-99.1 Page 50 of 104



EX-99.1 Page 51 of 104




EX-99.1 Page 52 of 104



EX-99.1 Page 53 of 104




EX-99.1 Page 54 of 104



EX-99.1 Page 55 of 104



EX-99.1 Page 56 of 104



EX-99.1 Page 57 of 104



EX-99.1 Page 58 of 104




EX-99.1 Page 59 of 104



EX-99.1 Page 60 of 104



EX-99.1 Page 61 of 104



EX-99.1 Page 62 of 104



EX-99.1 Page 63 of 104

## Regulatory Plan

## Proposed Indication


The Algostim Spinal Cord Stimulation (SCS) System is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.

## History

Company (Product)	Original PMA	Supplements
Medtronic (Itrel)	1984	233+
St. Jude (Genesis)	2001	65+
Boston Scientific (Precision)	2003	153+

## Plan

- Pursue PMA approval (literature based PMA)
- Utilize pre-IDE / PMA process
- Obtain CE mark
- TÜV (notified body) utilizing modular review process




http://www.sec.gov/Archives/edgar/data/1114483/000119312513114105/d503997dex991....

EX-99.1 Page 64 of 104




EX-99.1 Page 65 of 104



EX-99.1 Page 66 of 104



EX-99.1 Page 67 of 104




EX-99.1 Page 68 of 104



EX-99.1 Page 69 of 104



EX-99.1 Page 70 of 104



EX-99.1 Page 71 of 104



EX-99.1 Page 72 of 104



EX-99.1 Page 73 of 104






"A highly differentiated complete SCS system and platform with extensive offering of innovation, IP, advanced safety features, and future generation capabilities in the fast growing \$1.4B SCS market"

- 1% market share represents \$17M revenue to partner in 2015
- Highly under penetrated market (<10%)
- History of large market share shifts with technology innovation
- Strong SCS growth rate (7%+ CAGR)
- Extensive IP portfolio
- Gen 1: Technology innovation will drive market share
- Gen 2: Breakthrough technology can enable market leadership

cialize Medical Device Innovation



EX-99.1 Page 74 of 104

